Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826) - Concepedia

Concepedia

Publication | Open Access

Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

DOI Full Paper Access

11

Citations

0

References

2022

Year

Erika Hamilton, Jane Meisel, Carlos Alemany, B. Virginia, NU Lin, Robert Wesolowski, G. Mathauda-Sahota, D. Makower, Jeanette A. Lawrence, Demiana Faltaos,

European Journal of Cancer

No additional data available for this publication yet. Check back later!